Discovery Europe 2025

Overview Discovery Europe 2025

+co-located event:

Formulation & Delivery Europe 2025

Explore Discovery Europe 2025: Guiding Biopharma From Target Identification To Clinical Candidate

Connect & collaborate with 1000+ leaders in biology and chemistry at the renowned Discovery Summit in Basel, where we provide a platform to help you make informed pipeline decisions in early R&D & accelerate the route from target identification to novel clinical candidate, ultimately increasing the number of life-saving treatments for those with critical illnesses.

Together with Formulation & Delivery Europe, benefit from an event supporting you to identify potential formulation & delivery bottlenecks and issues before they arise and promoting collaboration to ensure the development of optimised drug products.

Download Agenda

Discovery Europe 2025

Across 12 specialized topic tracks and 100+ presentations, our congress touches on all aspects of the drug development journey, regardless of disease area or modality. Hear how experts are utilizing the latest technologies for target identification & validation and exactly how these are being translated into the preclinical phase. Gain exclusive insights into the current innovation in the space with novel large & small molecule targets, including ADCs, cell and gene therapies, PROTACs, molecular glues & more!

Packed with interactivity, networking and engaging talks, our Discovery Europe event will equip you with the knowledge & connections needed to keep ahead of the trends & make rapid advancements within your R&D.

Agenda at a Glance

Day 1

Track 1: Target Identification & Validation
Track 2: Medicinal & Computational Chemistry
Track 3: Translating Targets Into Therapies
Track 4: Novel Large Molecule Targets
Track 5: Targeting Neurodegeneration & Age-Related Disease
Track 6: Lab Digitalization & Connectivity

Day 2

Track 1: Functional Genomics & Cellular Technologies
Track 2: Hit Identification & Screening
Track 3: DMPK, Pharmacology & Safety
Track 4: Novel Small Molecule Targets
Track 5: Targeting Neuroimmunology & Neuroinflammation
Track 6: Implementing Automation & Robotics

Download Agenda

Formulation & Delivery 2025

Attendees of Discovery & Development Europe 2025 also have access to Formulation & Delivery 2025

Dive Into Formulation & Delivery 2025: Explore advancements in Product Development for Novel Drug Formats.

Join over 1000 cross-industry experts at Formulation & Delivery 2025 connecting pharmaceutical & biotech representatives as well as academia for high-level discussions on the latest innovations in pharmaceutical drugs formulation, drug delivery, RNA development & Peptides and Oligonucleotide design.

Across two days our programme will include 8 specialised topic areas diving into specific developments within the industry, from formulation strategies for cell and gene therapies, PROTACs and Nanotechnology to the latest advancements in enhancing bioavailability.

Our 11th Formulation & Delivery event will be co-located with Discovery Europe 2025 in Basel. Enjoy the collaboration as we support your engagement with discovery and formulation colleagues to ensure a smoother development of optimised drug products.

Agenda at a Glance

Formulation & Delivery 2025

Day One | Track 1: Small Molecule Formulation
Day One | Track 2: Large Molecule Delivery
Day One | Track 3: Preformulation Studies
Day One | Track 4: RNA Design & Delivery
Day Two | Track 1: Large Molecule Formulation
Day Two | Track 2: Small Molecule Drug Delivery
Day Two | Track 3: Process Chemistry & Pharmaceutical Materials
Analysis
Day Two | Track 4: Peptide & Oligo Design & Delivery

More Info

Good number of 1-1 meetings with relevant people. Very happy with the networking process and the Oxford Global team are very nice and service minded.

Regional Sales Director
AxionBio

Absolutely outstanding conference attracting large pharma and aspiring biotechs. Oxford Global are excellent, the food is outstanding and the preset meetings are informal and impactful

Vice President of Business Development
Arctoris

The organisation was perfect. Good mix between excellent scientific presentations and network opportunities.

Pharmacology Associate Director
Novalix

This was my first time at the conference and it was a great experience. Very well organized conference and I learned a lot and made valuable connection - Thank you Oxford Global.

Senior Principal Scientist
Novartis

1000

leading pharma, biotech & academic delegates

hours of presentations, discussions & interactive content

hours of networking breaks, including speed networking & refreshments

240

pre-arranged 1-2-1 meetings, facilitating business growth

What to Expect Engaging Thought Leadership

What to Expect Global Technological Showcase

What to Expect Innovative Poster Displays

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

Engaging Thought Leadership

Over 100 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
Global Technological Showcase

An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
Networking Emphasis

Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
Innovative Poster Displays

Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Today’s biopharma leaders must balance two priorities – acceleration (reducing the time from target ID to clinical candidate without compromising safety & efficacy) and innovation (bringing a consistent pipeline of novel drugs to market for difficult to treat diseases). This is at the heart of the 2025 programme, where we explore the newest methods, tools and strategies that will support scientists developing innovative therapeutics at speed. Expect:

Scientific & technical case studies highlighting best practice in every stage of the early R&D pipeline
Spotlights on novel targets making a splash – from small molecules beyond RO5 to innovative biologics
Deep dives on disease areas with the most unmet need, including a spotlight on targeting Neuroscience
Practical examples on how to implement automation & AI within R&D to improve lab productivity

Are you developing a cutting-edge therapy, platform or technology? Our Start-Up Zone is designed to support emerging companies looking to increase their visibility, find potential partners or early adopters, and meet their investment goals – connecting them with our community of pharma, investors, and mid-to-large size biotechs.

Located in the Exhibition Hall, the Start-Up Zone allows therapeutic pioneers to showcase their approach, conduct invaluable 1:1 meetings and deliver a quick-fire pitch.

We offer two options starting from €1800, based on the size of your organisation. To get involved, apply today and our Start-Up Lead will be in touch to discuss further. Alternatively, email Jordan at j.davies@oxfordglobal.com for more information.

Criteria:

The Start-Up Zone is designed for therapeutic start-ups, academic spin-outs, and early-stage technology/service providers.

To be eligible for inclusion, you must meet the following criteria:

• 0 – 5 years operating
• 0 – 30 employees
• Pre-Series A funding

What you will receive:

1 full conference pass
10-minute pitch in the Innovation and Collaboration track
1x1m space in Start-Up Zone for own partnering meetings; cocktail table provided, start-up to bring 1x pull-up banner
Logo featured on website & event platform as a participating start-up
Ability to arrange 1:1 meetings via the congress app

Join engaging presentations featured in our innovation and collaboration track running across day 2 and 3, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.

The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biomarkers discovery & development.

Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 20th December 2024
ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows:

Register and submit an abstract by 20th December 2024 using the registration link to the left on this page
Once registered you will be provided with the online abstract submission form
Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.)
The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event
The winners’ 10-minute oral presentations will take place during the networking drinks on day 2

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the Biomarkers series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights.

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Discovery Europe 2024: 22 - 23 May 2024, Basel, Switzerland

Berengere Dumotierd

Associate Director,

NOVARTIS

Davide Gianni

Senior Director,

AstraZeneca

Geoffrey Kerchner

Vice President,

F. Hoffmann-La Roche, Ltd.

Irene Choi

Head of Drug Discovery,

Verge Genomics

Janet Brownlees

Senior Director,

Merck Sharpe and Dohme

Johan Luthman

Executive Vice President of Research & Development,

Lundbeck

nils jakob vest hansen

ceo,

Vipergen ApS

Oliver Hucke

Associate Director,

Boehringer Ingelheim

Sanne Glad

Scientific Director,

Amgen Research Copenhagen

Simona Cotesta

Director,

Novartis

Show More Speakers

Hide Speakers

Amelie Joffrin

Investigator,

GSK

Anna Vulpetti

Associate Directir,

Novartis

Anto Pavlovic

Principal Research Associate,

Hoffmann La Roche Ltd

Arianna Sabò

Head of Research & Development,

QUANTRO Therapeutics

Ashutosh Dhingra

Staff scientist,

German Center for Neurodegenerative Diseases (DZNE)-Tübingen

Borislav Dejanovic

Senior Director,

Vigil Neuroscience

Carl Poelking

Associate Director,

Astex

CB Gurumurthy

Professor and Director,

University of Nebraska Medical Center

Daohong Zhou

Professor,

UTHSA

David Bearss

Chief Executive Officer,

Halia Therapeutics

Diana Zindel

Associate Director,

Astrazeneca

Eileen Wegner

Research Associate,

NMI Naturwissenschaftliches und Medizinisches Institut

Emma Davies

Associate Director - Preclinical,

Healx

Eric Goedken

Senior Principal Scientist,

AbbVie

Filip Roudnicky

Senior Principal Scientist,

Roche

Gebhard Thoma

Associate Director,

Novartis

Gergely Toth

Chief Executive Officer & Chief Scientific Officer,

Cantabio Pharmaceuticals

Giovanni Spagnolli

Chief Technology Officer,

Sibylla Biotech

Graham Dempsey

Chief Scientific Officer,

Quiver Bioscience

Gregori Gerebtzoff

Director,

Novartis

Hai Rao

Professor and Chair of Biochemistry,

Southern University of Science and Technology

James Overell

Group Medical Director,

Roche

Jon Lea

Team Leader,

GSK

Jonathan Mason

Senior Research Advisor,

Design for Drug Discovery

Jose Luis Molinuevo

Vice President Head of Experimental Medicine,

H. Lundbeck A/S

Julian Röwe

Senior Scientist,

AbbVie

Kerstin Hofer

Senior Scientist,

Roche

Manuel Stritt

Head Scientific Computing Drug Discovery,

Idorsia Pharmaceuticals

Markus Schade

Principal Scientist,

AstraZeneca

Morten Grunnet

Vice President, Head of Neuroscience and Professor,

H. Lundbeck A/S

Olivier Loiseleur

Senior Team Leader,

Syngenta

Olivier Kitten

Chief Executive Officer,

Affilogic

Olivier Bugaud

Senior Scientist Assay Development & Technologies,

Galapagos

Paulina Kolasinska-Zwierz

Principal Scientist,

Alchemab

Peter Brandt

Head of Chemistry,

Beactica Therapeutics AB

Richard Lewis

Director,

Novartis

Robin Loving

Chief Scientific Officer,

Salipro Biotech AB

Simon Huet

Senior Scientist,

Affilogic

Takhar Kasumov

Associate Professor,

NEOMED

Ulrike Künzel

Associate Principal Scientist,

Astrazeneca

Urs Langen

Laboratory Head,

Roche

Xinxin Gao

Principal Scientific Manager,

Genentech

The Role of Immuno-Organoids in Drug Discovery And Disease Modelling

A study conducted by Roche demonstrates how to create new human models with tissue-integrated immune cells.

Strategic Acquisition: Otsuka Pharmaceutical to Pay Up to $1.1 billion to Acquire Jnana Therapeutics' Drug Discovery Platform

The Japanese healthcare company Otsuka Pharmaceutical will acquire clinical-stage biotech Jnana Therapeutics.

Exscientia and Amazon Web Services Join Forces to Maximise the Potential Of Generative AI in Drug Discovery

Exscientia, a biotech and pioneer in technology-driven drug design, has teamed up with Amazon Web Services to bolster its AI drug discovery platform.

Building Partnerships & Fostering An Inter-Disciplinary Approach In The Fight Against Anti-Microbial Resistance

This article outlines two examples of partnerships that aim to tackle the global issue of anti-microbial resistance. This overlooked yet prominent threat continues to pose challenges for scientists, policymakers, and governments.

Advancing Drug Discovery Through Innovative Technologies & Strategic Collaboration

A Concise Report Featuring Insights From The Prominent Thought Leaders Of Discovery & Automate 2024

Paving the Way For Animal Free Models by Leveraging 3D Cell Culture, Organoids & Organ Modelling

A Concise Report Featuring Insights From The Prominent Thought Leaders Of 3D Cell Culture & Organ Modelling 2024

In-Person & Online Events

Online Activities

Speakers

Sponsors

Media Partners

In-Person Services

Digital Marketing Services

Browse All Resources

Latest Resources

The Role of Immuno-Organoids in Drug Discovery And Disease Modelling

Featured Resource

Advancing Drug Discovery Through Innovative Technologies & Strategic Collaboration

Discovery & Development Europe 2025

Discovery & Development Europe 2025

Discovery Europe 2025

Agenda at a Glance

Formulation & Delivery 2025

Agenda at a Glance

What to Expect

Engaging Thought Leadership

Global Technological Showcase

Networking Emphasis

Innovative Poster Displays

Introducing our 2025 Summit Theme: Innovation at Speed

Companies Represented Include

Introducing the Start-Up Zone

Criteria:

Biotech Innovation & Collaboration

Inspiring Tomorrow's Breakthroughs: Unleashing Innovation & Collaboration in Discovery Research & Development

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:

2025 Young Scientist Awards (YSA) for Best Poster Presentation

Meet Our Expert Speakers

Meet Our Esteemed Sponsors

Platinum Sponsors

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Network & Programme Sponsors

Interested in Sponsoring?

Latest Resources

The Role of Immuno-Organoids in Drug Discovery And Disease Modelling

Strategic Acquisition: Otsuka Pharmaceutical to Pay Up to $1.1 billion to Acquire Jnana Therapeutics' Drug Discovery Platform

Exscientia and Amazon Web Services Join Forces to Maximise the Potential Of Generative AI in Drug Discovery

Building Partnerships & Fostering An Inter-Disciplinary Approach In The Fight Against Anti-Microbial Resistance

Advancing Drug Discovery Through Innovative Technologies & Strategic Collaboration

Paving the Way For Animal Free Models by Leveraging 3D Cell Culture, Organoids & Organ Modelling

Plan Your Visit

Register Your Interest